Lantern Pharma Inc. (LTRN)

Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $36.57 million. The enterprise value is $23.08 million.

Market Cap	36.57M
Enterprise Value	23.08M

Important Dates

The last earnings date was Wednesday, November 12, 2025, after market close.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 11.18 million shares outstanding. The number of shares has increased by 0.29% in one year.

Current Share Class	11.18M
Shares Outstanding	11.18M
Shares Change (YoY)	+0.29%
Shares Change (QoQ)	+0.45%
Owned by Insiders (%)	0.41%
Owned by Institutions (%)	11.25%
Float	8.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.70
P/TBV Ratio	3.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.01.

Current Ratio	3.33
Quick Ratio	3.06
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -104.58% and return on invested capital (ROIC) is -67.24%.

Return on Equity (ROE)	-104.58%
Return on Assets (ROA)	-55.99%
Return on Invested Capital (ROIC)	-67.24%
Return on Capital Employed (ROCE)	-205.20%
Revenue Per Employee	n/a
Profits Per Employee	-$788,351
Employee Count	24
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.48% in the last 52 weeks. The beta is 1.60, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.60
52-Week Price Change	+3.48%
50-Day Moving Average	3.98
200-Day Moving Average	3.87
Relative Strength Index (RSI)	34.91
Average Volume (20 Days)	99,034

Short Selling Information

The latest short interest is 280,703, so 2.51% of the outstanding shares have been sold short.

Short Interest	280,703
Short Previous Month	259,396
Short % of Shares Out	2.51%
Short % of Float	3.27%
Short Ratio (days to cover)	1.56

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-19.67M
Pretax Income	-18.92M
Net Income	-18.92M
EBITDA	-19.65M
EBIT	-19.67M
Earnings Per Share (EPS)	-$1.75

Balance Sheet

The company has $12.36 million in cash and $93,954 in debt, giving a net cash position of $12.27 million or $1.10 per share.

Cash & Cash Equivalents	12.36M
Total Debt	93,954
Net Cash	12.27M
Net Cash Per Share	$1.10
Equity (Book Value)	9.59M
Book Value Per Share	0.87
Working Capital	9.42M

Cash Flow

In the last 12 months, operating cash flow was -$16.86 million and capital expenditures -$4,797, giving a free cash flow of -$16.86 million.

Operating Cash Flow	-16.86M
Capital Expenditures	-4,797
Free Cash Flow	-16.86M
FCF Per Share	-$1.51

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.29%
Shareholder Yield	-0.29%
Earnings Yield	-53.53%
FCF Yield	-47.71%

Analyst Forecast

The average price target for Lantern Pharma is $25.00, which is 664.53% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$25.00
Price Target Difference	664.53%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	3.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1